Search:

Filter:

Sort:

Fishy Peptide Freight: What Q1 2026 import data reveals

June 9, 2026

As the popularity of peptides skyrockets, consumers should be asking questions about where their drugs come from. Here’s what we found in shipment data for peptides in Q1.

June 8, 2026: Reckless physicians prescribing experimental, black market weight loss drugs: “Why are we waiting?”

June 9, 2026

Retatrutide, an experimental weight loss drug that hasn’t been submitted for FDA-approval, is being prescribed in weight loss clinics and med spas across the country.

Prescription Drug Freight Fraud, June 2026 report

June 9, 2026

March and April 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.

Fake medicines in Mexico, November 2025 – May 2026

June 5, 2026

Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.

Prescription Drug Affordability Board Activity, April-May 2026

June 4, 2026

Prescription Drug Affordability Board Activity, April and May 2026 Activities Summary Maryland: In its April meeting, the Maryland PDAB set a UPL on Jardiance. In its May meeting, the board set a UPL on Ozempic. Virginia: Virginia’s governor vetoed the highly anticipated bills that would have established a PDAB in her state. Colorado: The PDAB provided notice of UPL rulemaking for…

June 1, 2026: Up to 18 years for counterfeit pill conspirators in Massachusetts

June 2, 2026

The scheme, which produced counterfeit oxycodone, Adderall, and Xanax, is linked to over a dozen deaths, according to prosecutors.

May 26, 2026: Maryland PDAB passes a price cap on Ozempic, as Virginia’s governor questions board efficacy

May 27, 2026

Ozempic, the second drug that the state has set an upper payment limit on, will be capped at $274 for a 30-day supply.

Case overview: Gilead Sciences v Pain Relief Rx, et al (2026 — ) – ongoing

May 22, 2026

Gilead Sciences has filed a complaint against Pain Relief Rx and other companies that it alleges sold diverted medicines on pharmacy to pharmacy marketplaces.

May 18, 2026: FDA warns 503B compounding pharmacy for producing tirzepatide after shortage ended

May 19, 2026

The ProRx warning letter signals increased FDA scrutiny of compounded weight loss product that are not intended to be compounded in the US.

Safety risks in the GLP-1 market: an update on weight loss medication, May 2026

May 19, 2026

Criminal counterfeiters are exploiting Americans’ demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide, while compounders, telehealth companies, and med spas strain and skirt public health measures to meet high demand.